The Phivea™ Platform opens the door to future care and treatment of genetic disorders. Watch our brand new video on YouTube!
We are excited to announce that we have released a brand new video about the Phivea™ Platform, our innovative technology aiming to transform the diagnosis and treatment of genetic disorders.
Watch our colleagues Anne Kristine Schack, genomics researcher, and David Galevski, data scientist, guide you through the Phivea™ Platform, which we developed in strong collaboration with Netcetera, the University of Copenhagen and the Ss. Cyril and Methodius University in Skopje.
The Phivea™ Platform is a comprehensive decision support dashboard for healthcare professionals, which allows for timely diagnosis of genetic disorders and real-time prediction of clinical interventions. Phivea™ uses Oxford Nanopore Technology to classify genetic disorders and perform quality control on DNA reads. In particular, it allows real-time analysis of at least 384 samples simultaneously in less than 24 hours, meaning lower expenses for healthcare professionals and shorter path to diagnosis for patients. Phivea™ employs advanced Artificial Intelligence and customized Deep Learning architectures at all levels of the learning process, from feature extraction to assessment and follow-up care.
Watch our video on our gMendel® YouTube Channel.
04 Jan 2023gMendel® wins €500k grant from the EUROSTARS funding programme to develop a novel non-invasive prenatal screening tool for detection of genetic disorders powered by AI.
22 Dec 2022The Year in Review. As 2022 draws to a close, explore gMendel’s round-up of activities that dominated the year.
15 Nov 2022gMendel® announced today its first Board of Directors and appointments of Lars Staal Wegner, Chairman, and Hanna Pyokari, Member, effective November 1st, 2022.
27 Sep 2022gMendel® moves into an investment agreement with Polish biotech company genXone for further cooperation in diagnosis of genetic disorders.